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ABSTRACT 
 
Immune cell tumor infiltration represents one of the mechanisms that the immune system 
responds to tumor cells.  The tumor infiltrated immune cells include lymphocytes (TIL), 
dendritic cells (DCs), macrophages, and natural killer (NK) cells.  Although TILs have 
been extensively studied in order to develop adoptive transfer based immunotherapies, 
how to effectively isolate, culture, and in vitro boosting the killer cells from TILs remains 
a challenge. Meanwhile, OK-432, a heat and penicillin-treated lyophilized preparation of 
the low-virulence strain of Streptococcus pyogenes, has been shown to exhibit 
immunomodulatory activities and potential antitumor therapeutic function, including the 
activation of DCs, neutrophils, macrophages, lymphocytes, and NK cells as well as the 
induction of multiple cytokines production, such as IL-1, IL-2, IL-6, TNF-a, IFN-y, and 
IL-12. This research aims to establish an in vitro culture system, in which highly 
cytotoxic and tumor cells specific CTLs can be expanded, using OK-432, IL-2 and other 
cells and/or cytokines.  TILs were extracted from experimental mouse melanoma B16F0 
tumors grown on mice using two different methods. The isolated TILs were then cultured 
in vitro in four different culture conditions: 1) low dose IL-2, 2) low dose IL-2 + OK-432, 
3) low dose IL-2 + DCs, and 4) low dose IL-2 + OK-432 + DCs.  The cell count, 
phenotype, and cytotoxicity of these cultured TILs were evaluated using techniques 
including fluorescent activated cell sorting (FACS) and cytotoxicity assay. The results 
demonstrated that the additions of OK-432 and DCs into the culture system increased the 
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cell growth rate and the percentages of CD8+ cells in some culture conditions. More 
importantly, the addition of OK-432 and DCs into the culture system significantly 
increased the cytotoxicity of 14-day cultured TILs from 18% (low dose IL-2 alone), to 
44% (low dose IL-2 + OK-432), 40% (low dose IL-2 + DC), or 73% (low dose IL-2 + 
OK-432 + DC). Therefore, this research provides an improved in vitro TIL culture 
system that effectively enhances the cytotoxicity of the killer cells.  
Key words: Melanoma, TIL, Immunotherapy, IL-2, OK-432, CTL, DC 
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1. INTRODUCTION 
1.1 Overview of melanoma 
Malignant melanoma mainly occurs in skin but may also arise in the bowel and the eyes 
(Figure 1). Although it is not the most common type of skin cancer, it causes the majority 
of skin cancer-related deaths. Melanoma incidence and related death have been steadily 
increasing in the U. S. in recent years.  The lifetime risk estimate has reached 1 in 75 in 
the U. S.[1, 2]  While surgical excision is effective when primary tumors are thin, at least 
one third of patients with early stage disease will develop metastases. Patients with 
metastatic melanoma have a mean survival rate of six to eight months, with only 5% 
surviving more than year five.[3]  Therefore, great efforts have been made to improve 
treatments for metastatic melanoma patients.  Many agents have been investigated for 
antitumor activity in melanoma, but few have shown the response rate that is more than 
10%.  Among these new developments, immunotherapy has occupied a prominent place. 
In some studies significant tumor-specific immune responses were measured. [1, 3, 4] 
 
Figure 1. Melanoma develops in different cities, but mainly on the skin [5]  
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1.2 Tumor Infiltrating Lymphocytes (TILs) 
Many researchers believe that TILs represent the immune response to melanoma cells 
and other tumor cells.  This response is usually measured by the level of lymphocytic 
infiltratation present at the base of the vertical growth phase of the tumor and is 
sometimes categorized as brisk, nonbrisk, or absent.  The most brisk tumor-infiltrating 
lymphocytic response is always found in thin tumors. [6, 7] TILs are mainly composed of 
T lymphocytes as well as other subsets including: dendritic cells, macrophages, natural 
killer (NK) cells, and B lymphocytes.  T lymphocytes of TILs are mainly comprised of 
varying numbers of CD4+ helper and/or CD8+ cytotoxic T cells (CTL). [8, 9] TILs can 
play a key role in antitumor immune responses in the host by enhancing T lymphocyte 
cytotoxicity and inducing apoptosis in tumor cells. CD8+ TILs function in a tumor-
specific manner, while CD8+ T cells recognize antigens including tumor antigens and 
tumor associated antigens presented by MHC class I molecules. After recognition and 
activation, CTLs directly kill tumor cells by injecting lytic granules containing preforin 
and granzymes into target cells. They also deliver Fas ligand mediated death signals into 
tumor cells (Figure 2). Besides the direct killing, CTLs also release cytokinges that will 
destroy or help to destroy target cells.[6, 10, 11]   CD4+ TILs are also essential in order to 
establish and maintain the function of tumor-specific CD8+ TILs in tumor tissue.  CD4+ 
T cells (TH) recognize antigens, including tumor antigens and tumor associated antigens 
presented by MHC class II molecules.  Upon activation, CD4+ T helper cells release 
cytokines, which orchestrate immune responses (Figure 3). [7, 11] There is a third group of 
tumor infiltrated lymphocytes, which are CD4+ and CD25+. The function of this group 
of cells is immune suppression. [12]  It is possible that the ratio of CD4+/CD8+ T 
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lymphocytes is one of the key factors for appropriate function of TILs.  TILs also 
produce soluble cytokines such as interferon-γ for the cellular immune response. Some 
studies on IL-2-cultured TILs showed that the composition of TILs varies ranging from 
an infiltration with 90% CD4+ T cells to an infiltrate with 90% CD8+ T cells in 
individual patients.[9]  
 
Figure 2. CD8+ T cell pathway [13] 
 
Figure 3. CD4+ T cell pathway [13]  
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The work of Gershon and Kondo 1971 first identified the so-called "suppressor" cells. 
Sakaguchi et al. stirred interest in T regulatory cells (Tregs) by identifying CD4+ T cells 
highly expressing CD25, which are able to prevent autoimmunity in a murine model. [12, 
14, 15]  Tregs represent 5-10% of human CD4+ T cells.  Tregs have several subpopulations 
including naturally occurring CD4+CD25+ high Treg cells, induced Treg cells( Tr1 and 
TH3 cells), as well as CD4+CD25+ high Treg cells developed in the periphery by 
conversion of CD4+CD25– T cells.  A subpopulation of CD8+ cells is also classified as 
Tregs, but little is known about that subpopulation.[14, 16, 17]  All these Treg 
subpopulations coexist and contribute to immune suppression.  Among specific Treg 
markers, the transcription factor FOXP3 has been reported as uniquely expressed in Treg 
cells in mice. Therefore, CD4+/CD25+high/Foxp3+ can be the marker to identify 
Tregs.[14, 17]  CD4+CD25+high/FOXP3+ Tregs are characteristic in their anergic state 
(Figure 4.).  They are able to actively inhibit CD4+CD25– T cells, CD8+ T cells, 
dendritic cells (DCs), natural killer (NK) cells, natural killer T (NKT) cells, and B cells in 
a cell-to-cell contact and dose-dependent manner. Although Tregs contribute significantly 
to the maintenance of immune system homeostasis and tolerance to self-antigens, they 
may represent the main obstacle to immunotherapy for cancers because of their 
suppressive behavior to the other immune cells. [16-18] 
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Figure 4. Model for the suppression of conventional T cells by regulatory T cells [19] 
  
1.3 The function of IL-2 
One of the most important growth factors of TIL are interleukin (IL)-2, which have been 
studied for more than 20 years in the therapy of melanoma.  High dose IL-2 therapy has 
been developed to treat metastatic melanoma patients. [20-22]  Some patients displayed 
significantly positive immune responses to the treatment and tumor regression was 
observed in these patients, although the relative response rate among patients is still very 
low. [20-22] Another advantage of this treatment is that once the initial treatments are 
complete, remission can be gained and further maintenance therapies are not needed. 
However, in some cases, the surgical removal of residual disease is required. [20, 22] This 
treatment also has some very severe side effects such as vomiting, nausea, diarrhea, 
fatigue and flu like symptoms such as fever, chills, and muscle aches. [22, 23] Despite the 
miserable side effects, the treatment typically does no permanent damage.  Some 
researchers have developed high or low dose IL-2 plus other reagents or immune peptides 
treatment such as gp100 analogue peptide.[22, 24]  Compared to the IL-2 only treatment, 
response rate and progression-free survival rate were significantly higher.  Also, the 
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reduction of administrated dose of IL-2 can significantly reduce the side effects.  All of 
the aforementioned studies suggest that the treatments combining IL-2 with other 
reagents or immune peptides are the right track for the immunotherapy of melanoma. [21, 
25, 26] 
 
Smith et al. indicated that IL-2 can enhance the proliferation rate of antigen specific TILs 
and/or their cytotoxicity. [27]   To expand the effective T cells in vitro, IL-2 must be added 
during culture as a growth factor.  T cells produce IL-2 following antigen presentation, 
and also express IL-2 receptor on their surface.  The growth, differentiation, and survival 
of antigen selected T cells can be stimulated by IL-2 and IL-2 receptor interaction.  T cell 
immunologic memory and induction of regulatory T cell activity also require IL-2. [21, 28, 
29] Additionally, IL-2 can induce the differentiation and proliferation of natural killer (NK) 
cells and facilitate the production of antibodies by B cells.  The Food and Drug 
Administration (FDA) approved recombinant IL-2 for the treatment of metastatic renal 
cell carcinoma and melanoma in 1992. [21, 28, 29] 
 
Although IL-2 is widely used in the cultivation and expansion of T cells, the 
concentrations of IL-2 vary greatly among different studies from 10 IU/mL to 6000 
IU/mL.  Several studies have compared the effect of different IL-2 concentrations on the 
proliferation rate of T cells but not on cytotoxicity function.  A recent paper reported that 
T cell cultures grown in very high IL-2 concentrations (600-6000 IU/mL) had the highest 
proliferation rate and secreted the most interferon (IFN)-r in response to antigenic 
stimulation but exhibited lower direct cytotoxicity. [27]  On the contrary, TIL cultures 
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grown in low concentrations of IL-2 (10-600 IU) had a lower proliferation rate and rarely 
secreted IFN-r but displayed higher cytotoxic activity. [27] The author also used a 
combined approach, starting with low concentration of IL-2 (10-120 IU) the first week, 
then increasing the IL-2 concentration to 6000 IU/mL during the second week. In this 
way, T cells expanded well, maximally produced IFN-r and were highly cytotoxic against 
tumor cells. [27] 
 
 1.4 The function of DCs 
Dendritic cells (DC), originating from bone marrow, are one kind of antigen presenting 
cells (APC’s) and one of the best equipped APCs to prime the response of T cells because 
they can constitutively express MHC II antigens and numerous T cell co-stimulatory 
molecules. [30] Immature DCs are phagocytic cells that can sample antigens at the site of 
injury or infection and migrate to secondary lymphoid organs, where they can present 
antigens to T cells.  However, immature DCs are weak immunogens and can even induce 
the antigen-specific Tregs. Mature DCs on the other hand have surface stimulatory 
molecules such as CD40, CD80, CD86 and some adhesion molecules. Upon activation, 
DCs can migrate to the lymphoid tissues where they interact with T cells and B cells to 
initiate and shape the adaptive immune response. [30-32]  
 
1.5 Coley’ toxin and OK-432 
It was reported that acute bacterial infection can induce regression in some malignant 
tumor long time ago. Based on this work, Busch infected a patient with soft tissue 
sarcoma with erysipelas in 1868, and rapid tumor shrinkage was observed after infection 
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[33].  However, this response was only partial and tumor recurrence subsequently occurred. 
Streptococcus was identified as the causative agent of erysipelas 13 years later. [33, 34] 
 
Dr. William B. Coley, a New York surgeon found a substantial number of this kind of 
publications in 1890s and started his own research. He infected Streptococcus to an 
inoperable patient who had an extensive lymphoma of the neck. He observed that the 
tumor underwent extensive necrosis, although with sever erysipelas after infection. The 
patient remained disease-free for 8 years.  Encouraged by this outcome, he injected 
Streptococcus to treat patients with a variety of malignant tumors. [34] The clinical results 
were variable. He observed that different tumor types had different outcomes and the 
severity of infection also highly affect the result. He also noticed that the presence of 
Serratia marcescens can improve the outcome. He incorporated Serratia marcescens into 
the Streptococcal vaccine.  The combined injection of these two heat-killed bacteria was 
called “Coley's toxin” since then. [35] 
 
Coley concluded that the infection induced a systemic response, which led to tumor 
destruction. Administration of the toxin was very complicated and may result in 
significant morbidity and even mortality. High fever is essential for a good outcome. [34, 
35] After treating various kinds of tumors, he noticed that the best response was from 
patients with inoperable soft tissue sarcomas. The five years disease-free survival rate 
was approximately 50%. [34, 35] 
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Coley's observations illustrated that acute infection may lead to stimulation of immune 
response of the host. This results in recognition of the tumor by the immune system, 
initiation of immune response to tumors, and tumor destruction. [34] However, Coley’s 
toxin was abandoned long ago, mainly to avoid life-threatening infection.  Contemporary 
science still cannot define the active elements in Coley’s toxin, and attempts to improve 
safety such as heat treatment, resulted in diminished clinical efficacy.  Some researchers 
suggested that plasminogen might be activated by administration of fresh Streptococcus 
which leads to the regression of tumors. [36] 
 
One of the plasminogen activators is streptokinase (SK) whose activity may be lost after 
purification and heat treatment, due to elimination of live bacteria.  SK is produced by 
virulent and when combined stoichiometrically with host plasminogen leads to the 
formation of enzymically active plasmin.  The function of plasmin, which has relatively 
broad substrate specificity, is to initiate some protease cascades and degrades various 
plasma and extracellular matrix proteins.  At the same time, SK could function as a 
streptococcal spreading factor which facilitates the dissection of organisms through tissue 
planes. [37]  Some studies show that a host factor, which may be plasminogen, is needed 
for the antitumor effect. [38, 39]  Some researchers suggest that administrating of SK or 
other plasminogen activators, or plasmin may reproduce the systemic streptococcal 
infections.  There are several possible mechanisms of plasminogen on antitumor effects 
such as a direct cytoxicity to tumor cells, disruption of the tumor extracellular matrix, 
alteration of tumor growth factor activity, and inhibition of metastasis.  Besides SK, other 
  10
plasminogen activators are being tested in the lab, including LPS, which is widely used to 
activate DCs in the lab, and OK-432. [37-39] 
 
OK-432, developed by Okamoto et al., is a heat and penicillin-treated lyophilized 
preparation of the low-virulence strain Su of Streptococcus pyogenes. OK-432 has 
immunomodulatory and potential antitumor therapeutic function by activating DCs, 
neutrophils, macrophages, lymphocytes, and NK cells, as well as inducing multiple 
cytokines including IL-1, IL-2, IL-6, TNF-a, IFN-y, and IL-12.  It has been reported that 
OK-432 can improve the antitumor function induced by a granulocyte-macrophage 
(GM)-CSF gene-modified tumor vaccine. [40-46]  OK-432 has also been used clinically in 
Japan as an adjuvant treatment for patients with lung cancer, esophageal cancer, 
gastrointestinal cancer, bladder cancer, and peritoneal carcinomatosis. A great 
improvement has been made in cancer survival rate when immunotherapy and OK-432 
are concomitantly used with chemotherapy. However, the precise mechanism of OK-
432’s anti-cancer activity remains unknown.  OK-432 has not been approved by FDA to 
be used in the U. S. at the time of this publication. [47, 48] 
 
1.6 Cellular immunotherapy 
Cellular immunotherapy (CI) started with the use of lymphokine-activated killer cells 
(LAK) in the early 1980s and advanced to the use of immunologically specific, tumor-
infiltrating lymphocytes (TIL) today. One of the recent immunotherapy strategies 
consists of expansion of large numbers of autologous tumor reactive lymphocytes (TILs 
from tumors or peripheral blood) ex vivo and subsequently reinfused those cells into the 
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patients’ circulatory system. [6, 7, 49, 50]  Melanoma is an ideal tumor model for studying CI 
because of the relatively easy melanoma-TIL culture conditions and the higher frequency 
of clinical responses. [51] Tumor-specific CD4+ and/or CD8+ T cells can be harvested 
from the culture of enzymatically digested tumor biopsies with high concentration IL-2.  
Stable long-term tumor cell lines also can be derived from harvested cells which make 
detailed immunologic analysis easier.  Antitumor TIL can be derived from different sites 
such as cutaneous and visceral lesions. [7, 51, 52] 
 
At the beginning of CI therapy, people hoped that more durable clinical successes in a 
wider range of tumor types could be achieved. TIL transfer therapy was considered by 
many researches to be the most promising immunotherapeutic strategy.  Successful tumor 
eradication in murine models has been achieved by this strategy. [6]  Unfortunately, this is 
not the case in clinical practice. TILs extracted and expanded from tumor tissues are 
sometimes composed of quiescent and/or functionally anergic T cells. They are unable to 
persist or perform their immunosurveillance function after adoptive transfer and 
consequently, they fail to co-deliver effective cytoreductive and/or immunosuppressive 
chemotherapy, especially when non-specific T cell populations are used. The function of 
TILs is always weakened by the accumulation of Tregs, which are able to actively inhibit 
the function of TILs. Tumor burden contributes to a significant tumor and/or host derived 
suppressive environment which is also a reason to dampen the initial hope. [8, 9, 49, 50]         
 
TIL treatment showed little effect in colon cancer, esophageal cancer, breast cancer, 
follicular lymphomas, ovarian cancer, renal cell cancer, and non-small cell lung cancer. 
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This is likely due to non-specific TIL or TIL with no functional reactivity being the only 
products obtained, despite using standard TIL culture conditions. This is due to the 
experimental inability to remove fresh tumor cells from the mixture.  [7, 9, 51] 
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2. MATERIALS AND METHODS 
2.1 Mice, cell line, and reagents 
C57BL/6J mice (male or female) at 6–8 weeks of age were purchased from Jackson 
Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities. The 
animal experiments were carried out in accordance with the Guidelines for the Care and 
Use of Laboratory Animals (NIH Publication Number 85-23), and institutional guidelines. 
B16F0 mouse melanoma cells (ATCC #CRL 6322, Rockville, MD) were cultured in 
DMEM (GIBCO BRL, Grand Island, NY) containing 10% fetal bovine serum (FBS, 
Hyclone, Logan, Utah) and 50 μg/ml of gentamicin (GIBCO BRL). Recombinant mouse 
IL-2 (mIL-2, herein refered to as IL-2) (Cat. No. 402-ML) was purchased from R&D 
(Minneapolis MN). β2-microglobulin (Cat. No.058K0814) was purchased from Sigma (St. 
Louis, MO). RPMI 1640 (Cat. No.10 -040-CU) was purchased from Mediateeh 
(Manassas, VA). Dynalbeads FlowCompTM Mouse Pan T (CD90.2) (Cat. No. 114.65D) 
was purchased from Invitrogen (Oslo, Norway). Sodium pyruvate (Cat. No. 25-000-C1) 
was purchased from Mediateeh (Manassas, VA). Hepes Hyclone (Cat. No. SH30851.01) 
was purchased from Hyclone Laboratories, Inc (Logan, Utah). Amino acids (Cat. No. 
SH30238.01) was purchased from Hyclone Laboratories, Inc (Logan, Utah). GiBco 
12605 TrypLE Red (Lot. No. 564859) was purchased from Invitrogen (Oslo, Norway). 
All of the antibodies of CD3, CD4, CD8, CD25 Foxp3, CD19, CD80 and CD86 were 
purchased from BD Pharmingen TM (San Jose, California). 
 
2.2 Extraction of TILs from tumor 
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Two different procedures were employed in the study to isolate TILs, i.e., ficol gradient 
centrifugation method and Dynabeads® FlowComp™ Mouse Pan T method. 
2.2.1 Ficol gradient centrifugation method 
To extract TILs from mice melanoma tumor tissues, 1×106 B16F0 tumor cells were 
subcutaneously injected to each of 4 female C57BL/6J mice two weeks before harvesting 
the tumor tissue.  The mice were euthanized and the tumor tissues were aseptically 
dissected and cut into small pieces in a petri dish. 20 ml of digestion solution 
(collagenase, 1.4 mg/ml and DNase, 0.392 mg/ml) were added to the tumor tissues. The 
digestion suspension was transferred into a T-75 flask and incubated at 37°C for 2 hrs 
with slow shaking.  The cell suspension was strained using a 70 µm cell strainer to 
remove un-digested tissues.  The cells were then washed twice with all free DMEM by 
spinning at 900xg for 10 min each time.  The cells, resuspended in 20 ml all free DMEM 
were gently added over 15 ml of ficol in a 50 ml centrifuge tube without disturbing the 
interface.  The tubes were centrifuged at 900xg for 30 min with brake off.  Cells at the 
interface after centrifugation were carefully collected, washed twice with all free DMEM, 
and resuspended in culture medium containing 10% FBS. In order to isolate T cells, the 
cell suspension was added onto a nylon wool column and incubated at 37°C for 1h. The 
cells that passed through (mainly T lymphocytes) were collected into a new tube, washed 
twice with all free DMEM and resuspended in 10ml cell culture medium with 10% FBS. 
2.2.2 Dynabeads® FlowComp™ Mouse Pan T method  
To extract TILs from mice melanoma tumor tissues, 1×106 B16 cells were 
subcutaneously injected into each of 4 female C57BL/6J mice two weeks before 
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harvesting the tumor tissue.  The mice were euthanized and the tumor tissues were 
aseptically dissected and cut into small pieces in a petri dish.  The tumor tissues were 
then ground by using the coarse part of 2 glass slides, the cell suspension was passed 
through a 70 µm cell strainer.  After two times of washing with all free DMEM, the cells 
were resuspended in 15 ml ammonia-chloride-potassium (ACK) solution (ACK lysis 
buffer: 0.15 M NH4Cl; 1.0 mM KHCO3; 0.1 mM Na2EDTA; pH 7.2) to remove red blood 
cells and then resuspended in isolation buffer from the dynabeads FlowComp Mouse Pan 
T (CD90.2) kit at a concentration of 1x108 cells/ml.  
 
FlowComp™ Mouse CD90.2 Antibody from the kit was added into the cell suspension at 
a ratio of 25 µl antibodies per 500 μl cell suspension (5×107 cells), mixed well and 
incubated for 10 minutes at 2–8°C.  After incubation, cells were washed by adding 2 ml 
of isolation buffer and centrifuging at 900xg for 8 min and resuspended in 1 ml isolation 
buffer. 75 μl of resuspended FlowComp™ Dynabeads were added into the tube, mixed 
well, and incubated for 15 min at room temperature with rolling and tilting.  The tube was 
then placed on a magnet for a minimum of 1 min. With the tube still on the magnet, the 
supernatant was carefully removed and discarded. The washing step was repeated once. 
The tube was removed from the magnet and the cell pellet was carefully resuspended 
with 1 ml FlowComp™ Release Buffer and incubated for 10 min at room temperature 
under rolling and tilting.  The tube was placed on the magnet for 1 min, and the 
supernatant containing the bead-free cells (TILs) was transferred to a new tube. The cells 
were then washed with 2 ml of isolation buffer by centrifuging at 900xg for 8 min and 
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responded in cell culture medium with 10% FBS. The cell suspension was kept on 2–8°C 
until further use in downstream applications. 
 
2.3 Culture of dendritic cells from bone marrow  
To improve cytotoxicity, DCs were added into the culture medium.  To extract DCs from 
mice, the mice were euthanized in CO2 chamber. Femur and tibia bones were dissected 
and placed in a small petri dish.  5-10 ml (for bones of 1 mouse) of all free RPMI was put 
in a petri dish.  The bone marrow cells were passed through a 40 µm cell strainer into a 
50 ml tube. After washing twice with 10 ml all free RPMI medium by spinning at ca. 
700xg for 5 min, the cells were resuspended with 10 ml of ACK lysis buffer for cell from 
the bones of one mouse and incubated at room temperature for 5 min.  After another two 
wash cycles, the cells were resuspended in 10 ml of DC medium and cultured at 37oC for 
6 days with addition of 10 ml DC medium into the culture dish on day 4.  On day 6, 10 
ml of medium were gently removed from the dish and 10 ml DC medium containing LPS 
(200 ng/ml), which activates DCs, was added into the dish. The cells were then further 
cultured for 24 to 48 hrs. 
 
2.4 Culture of TIL cells  
In order to expand the TILs isolated from tumors in vitro using different methods as 
described above, the cells were cultured in four different culture conditions. 
2.4.1 Culture condition A: IL-2 alone 
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Cells were cultured in RPMI with 10% FBS, 10 mM MOPS, 0.05 mM 2-ME, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 216 mg/l L-glutamine, 116 mg/l L-arginine, 36 mg/l 
L-asparagine, 6 mg/l colic acid, 110 mg/l sodium pyruvate, 2 g/l NaHCO3.  IL-2 at a dose 
of 400 IU/ml was also added into the medium. Cultures were maintained in 5% CO2 at 
37°C for up to 4 weeks for most of the studies. When necessary, the cells were cultured 
longer. 
2.4.2 Culture condition B: IL-2 + OK-432  
Culture condition B was the same as Culture condition A except OK-432 at a 
concentration of 1 µg/ml was added. Cultures were maintained in 5% CO2 at 37°C for up 
to 4 weeks for most of the studies. When necessary, the cells were cultured longer. 
2.4.3 Culture conditions C: IL-2 + DC  
In culture condition C, activated DCs were added into the culture system as Culture 
Condition A at a TIL to DC ratio of 10 to 1. Cultures were maintained in 5% CO2 at 37°C 
for up to 4 weeks for most of the studies. When necessary, the cells were cultured longer. 
2.4.4 Culture condition D: IL-2 + OK-432 + DC  
Culture condition D was the same as Culture condition C except OK-432 at a 
concentration of 1 µg/ml was added into the culture medium.  Cultures were maintained 
in 5% CO2 at 37°C for up to 4 weeks for most of the studies. When necessary, the cells 
were cultured longer. 
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2.5 Fluorescent Activated Cell Sorting (FACS) analysis  
To phenotypically characterize TILs, freshly isolated cells and cells cultured for various 
length of time in different culture conditions were subjected to the FACS analysis. 2×105 
cells from each sample were collected and washed twice with FACS staining buffer. 
Different antibodies (1 µg/1x106 cells) were added to the cells in 50 µl staining buffer 
and incubated for 30 min on ice. After staining, the cells were washed twice with staining 
buffer and resuspended in 500 µl of staining buffer and analyzed with FACS Calibur 
using CellQuest software.  The following antibodies or their combinations were used: 
Isotype controls, H-2Db-FITC, H-2Db-PE, CD3-PE, CD4-PE/CD3-Cy5, CD8-PE/CD3-
Cy5, CD25-PE/CD3-Cy5, Faxp3/CD3-Cy5. 
In order to stain the intracellular antigen, Foxp3, after the CD3-Cy5 staining, the cells 
were washed twice with the staining buffer, treated with BD’s CYTOFIX CYTOPEM on 
ice for 30 min, and stained with Foxp3- PE overnight on ice.   
Before putting into culture, DCs were also analyzed with FACS using antibodies of 
CD33, CD80 and CD86. 
 
2.6 Cytotoxicity analysis 
The cytotoxicity of TIL cells, fresh or cultured in various culture conditions, was 
measured by a standard 51Cr release assay using B16F0 tumor cells as target cells.  2x106 
B16F0 cells were collected, washed twice with PBS, and resuspended in 0.1 ml culture 
medium containing 20% FBS. 100 µCi of 51Cr were added into the cell suspension. The 
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tube was gently mixed and incubated at 37oC for 1h with gentle mixing every 20 min to 
allow for cellular uptake of 51Cr. The cells were washed twice with PBS and resuspended 
in RPMI medium at a concentration of 5×104 cells/ml. 100 µl of the cells (5x103 cells) 
were transferred to each well of 96-well round bottom plate. While labeling the target 
cells, the effector cells were prepared at concentrations of 5.5x105 /ml, 1.5x105 /ml, and 
5x104 /ml, respectively.  100 µl of each effector cells were added into corresponding 
wells which contain 100 µl of the labeled target cells so that the effector to target ratio 
was 11:1, 3:1, and 1:1.  After spinning for 30 sec at 228xg to settle the cells, the plate was 
incubated at 37oC for 4 hrs.  30 min before finishing the incubation, 100 µl of 2% Triton-
100 was added into some of the wells containing only the target cells as maximum 
release control.  After spinning at 228xg for 2 min, 50 µl of the supernatant from each 
well were transferred into a new plate correspondently, and 150 µl of the scintillation 
liquid were added into each well. The radioactivity of the samples was measured with the 
Trilux scintillation counter.  The cytotoxicity of the killer cells was calculated as: 
 
CPM denotes for count per minute. 
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3. RESULTS 
3.1 Yield and phenotype of TILs isolated with different methods 
Several experiments using the ficol gradient centrifugation method were performed.  The 
isolated TIL cells were stained with different antibodies and analyzed by FACS. Since 
there were many tumor cell contaminants present in the TIL cell preparation, anti-CD3 
antibody was used to gate T cells in the FACS analysis.  As shown in Table 1, 42% of the 
CD3+ cells are CD4+ and 35% of the CD3+ cells are CD8+. CD25+ cells accounts for 
17% and Foxp3+ cells accounts for 7%. 
Since the ficol gradient centrifugation method leaves many tumor cells in the TIL 
preparation, we employed the Dynabeads® FlowComp™ Mouse Pan T method. This 
method positively selects for all T cells using a pan T antibody, anti-CD90.2. As 
expected, this method generated highly pure T cells with no tumor cell contaminants 
present in the preparation. As shown in Table 2, 37.07% of the CD3+ cells are CD4+ and 
41.22% of the CD3+ cells are CD8+. CD25+ cells accounts for 2.07% and Foxp3+ cells 
accounts for 0.07%.  The problem of this method is the limited yield of TILs.  
Table 1: Phenotype of fresh TILs isolated using the ficol gradient centrifugation method 
CD4+ CD8+ CD25+ Foxp3+ 
42.00% 35.23% 17.58% 7.31% 
 
Table 2: Phenotype of fresh TILs isolated using the Dynabeads® FlowComp™ Mouse Pan 
T protocol. 
CD4+ CD8+ CD25+ Foxp3+ 
37.07% 41.22% 2.07% 0.07% 
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In conclusion, the Dynabeads® FlowComp™ Mouse Pan T method seems to be the 
better choice to isolate TILs from mouse tumor tissues. As a result, most of the following 
experiments were performed with TILs isolated using this method. However, since only 
90.2+ cells are selected, some functional TILs in the tumor tissue may be lost. 
 
3.2 IL-2’s role on expansion, phenotype, and cytotoxicity of cultured TILs 
3.2.1 Cell count and surface marker of cultured TIL with low dose IL-2 
In this culture condition, TILs grew fast in the first week (290%) and second week (130%) 
and then slowed down. (Table 3) The growth rate reported for each week was calculated 
based upon the amount of cells in the week prior to amount of cells of the week. The 
reason is that certain amounts of cells were taken out of the cell culture to perform 
experiments. The percentages of CD4+ cells and CD8+ cells in the culture decreased 
significantly (from 37% to 5% and from 41% to 12%, respectively), while CD25+ cells 
increased significantly from 2% to 35% (Table 4), which means the cells that expressed 
CD25+ were activated. 
Table 3. Cell count of cultured TILs in low dose IL-2 (400 IU/ml) 
Time Cell Count (cells/ml) Growth Rate
Week 0 0.4 x106 --- 
Week 1 1.4 x106 290% 
Week 2 2.9 x106 130% 
Week 3 1.7 x106 -24% 
Week 4 1.1x106(from 1.3 x106) -24% 
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Table 4. Phenotype of cultured TILs in low dose IL-2 (400 IU/ml) 
Time CD4+ CD8+ CD25+ Foxp3+
Week 0 37.04% 41.22% 2.07% 0.07% 
Week 2 1.54% 12.77% 6.62% 0.04% 
Week 4 5.15% 12.64 35.05% ND 
ND, not detectable. 
3.2.2 Cytotoxicity of cultured TIL with low dose IL-2 
TILs cultured for 14 days and 28 days in low dose IL-2 were harvested and used to 
perform a cytotoxicity assay using B16F0 tumor cells as target cells. Due to the limitation 
of cell numbers, only three effector to target ratios were evaluated: 11:1, 3:1 and 1:1.  As 
shown in Figure 5, the cytotoxicity of TILs cultured in this condition is relatively low 
(less than 20%), although the cytotoxicity of 14-day cultured TILs (18%) is higher than 
that of  28-day cultured TILs 12% at the effector to target ratio of 11:1. 
 
 
 
 
Figure 5. Cytotoxicity of TILs cultured in low dose IL-2 (400 IU/ml) for 14 and 28 days. 
 
 
 
14 days
28 days
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3.3 OK-432’s role on expansion, phenotype, and cytotoxicity of cultured TILs 
 3.3.1 Cell count and surface marker of cultured TIL with OK-432 
As illustrated on Table 5, when OK-432, at a concentration of 1µg/ml, was added into the 
TIL culture together with low dose IL-2 (400 IU/ml), cell growth was promoted. More 
importantly, under this culturing condition we were able to culture the TILs for up to 14 
weeks and maintain cell growth. (Table 5) Under this culture condition CD4+ cells 
decreased significantly, similar to the IL-2 alone culture condition.  CD8+ cells increased 
significantly in the first two weeks of culture, in contrast to the IL-2 alone culture 
condition. (Table 6) 
 
Table 5. Cell count of cultured TILs in low dose IL-2 (400 IU/ml) plus OK-432 
Time Cell Count (cells/ml) Growth Rate
Week 0 0.6x106 0 
Week 1 1.9x106 217% 
Week 2 2.93x106 54% 
Week 3 4.62x106 58% 
Week 4 3.24x106 (from 1x106) 224% 
Week 5 2.85x106 (from 1x106) 185% 
Week 6 4.85x106 70% 
Week 7 4.62x106 -5% 
Week 8 3.57x106 -23% 
Week 9 2.5x106 (from 1x106) 150% 
Week 10 1.13x106 -55% 
Week 11 2.35x106 52% 
Week 12 2.8x106 19% 
Week 13 1.71x106 -39% 
Week 14 1.13x106(from 0.55x106) 105% 
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Table 6. Percentages of different cells in cultured TILs in low dose IL-2 (400 IU/ml) plus 
OK-432 
Time CD4+ CD8+ CD25+ Foxp3+
Week 0 37.04% 41.22% 2.07% 0.07% 
Week 1 1.62% 73.62% 41.01% 1.06% 
Week 2 0.35% 63.31% 27.53% 0.72% 
Week 3 0.24% 48.97% 32.96% 0.25% 
Week 4 0.79% 36.49% 35.79% 1.84% 
 
3.3.2 Cytotoxicity of cultured TIL with OK-432 
TILs cultured for 14 days and 28 days in low dose IL-2 plus OK-432 were harvested and 
used to perform a cytotoxicity assay using B16F0 tumor cells as target cells. Due to the 
limitation of cell numbers, only three effector to target rations were performed: 11:1, 3:1 
and 1:1.  As Figure 6 shows, both of the effector cells collected from day 14 culture and 
day 28 culture had significant killing of the target tumor cells. When the effector to target 
ratio is 11:1, the cytotoxicity reached 44.2% and 42%, respectively. This cytotoxicity is 
significant higher that of TILs cultured in IL-2 alone culture condition (19% and 12%, 
respectively). 
                                                                               
Figure 6. Cytotoxicity of TILs cultured in 400 IU/ml IL-2 and 1 µg/ml OK-432 for 14 and 28 
days. 
14 days
28 days
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3.4 Dendritic cell’s role on cytotoxicity of cultured TILs 
In order to further improve the cytotoxicity of TILs cultured in low dose IL-2 and OK-
432, bone marrow derived dendritic cells were added into the culture system. The 
cultured cells were harvested at various time points and used to perform the cytotoxicity 
assay using B16F0 tumor cells as target cells. The cytotoxicity of TILs cultured in low 
dose IL-2 with DCs for 14 and 28 days is shown on Figure 7. The cytotoxicities of TILs 
cultured under this condition for 14 and 28 days are 40% and 60%, respectively. Figure 8 
shows the cytotoxicity of TILs cultured in low dose IL-2 with DCs plus OK-432. When 
the ratio of effector to target was 11:1, the cytotoxicities of TILs cultured in this 
condition reached 73% and 57%, respectively. 
 
 
 
 
 
Figure 7. Cytotoxicity of TILs cultured in low dose IL-2 (400 IU/ml) and DCs (TIL:DC=10:1) 
for 14 and 28 days. 
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Figure 8. Cytotoxicity of TILs cultured in low dose IL-2 (400 U/ml), 1 µg/ml OK-432 and DCs 
for 14 and 28 days. 
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4. DISCUSSION 
Although TIL therapy has achieved notable progress in treatment of melanoma in 
preclinical animal models, the clinical outcomes are not always promising. [6] Researchers 
have developed several new ideas to enhance the proliferation and cytotoxicity of the 
cultured TILs by adding different concentrations of IL-2 or GM-CFS and/or other 
cytokines to the culture. [7, 9]  This project was designed to establish an in vitro culture 
system in which highly cytotoxic and tumor cell specific CTLs can be expanded, while 
inhibiting Tregs by using OK-432, IL-2 and other cells and/or cytokines. Experimental 
subcutaneous tumors of mouse B16F0 melanoma were developed in mice and T 
lymphocytes of TILs were extracted from tumors directly. The isolated cells were then 
cultivated in four different culturing conditions.  The first challenge was how to 
effectively isolate highly pure TILs with sufficient amount from tumor tissues.  Many 
studies have used ficol gradient to separate TILs from tumors. However, many TILs are 
lost in the ficol centrifugation step.  Another challenge is that the cell preparations from 
ficol gradient contain many tumor cells, and it is difficult to separate TILs from tumor 
cells.  In this work, we first used the ficol gradient approach to isolate TILs from tumor 
tissues. Although a significant number of TILs was obtained, the cell preparation 
contained many tumor cells. Furthermore, TILs contain T cells, B cells and NKs etc.[8, 9]  
Our main goal is to separate T cells.  It is also challenging to eliminate other lymphocytes 
from TILs as well.  We then employed another method to isolate T lymphocytes directly 
from tumor tissues, i.e., the Dynabeads® FlowComp™ Mouse Pan T method. Our data 
support that the Dynabeads® FlowComp™ Mouse Pan T protocol represents a better 
method, although it risks losing some functional T cells. 
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Many researchers believe that TILs represent the immune response to tumor cells.  TILs 
are mainly composed of T lymphocytes and other subsets.  T lymphocytes of TILs are 
mainly comprised of varying numbers of CD4+ helper and CD8+ cytotoxic T cells (CTL). 
[6-9]  In order to expand T cells from TILs in vitro, many researchers used IL-2 in their 
culture systems.  The concentration of IL-2 used in culture becomes a major issue. It is 
debated whether high dose IL-2 (over 1000 IU/ml) or low dose IL-2 (lower than 600 
IU/ml) is better in terms of enhancing the proliferation rate and cytotoxicity of T cells.[27]  
A recent paper reported that T-cell cultures grown in very high IL-2 concentrations (6000 
IU/ml) had the highest proliferation rate but exhibited lower direct cytotoxicity.  On the 
contrary, T cells grown in low concentrations of IL-2 (600 IU/ml) had a lower 
proliferation rate but displayed higher cytotoxicity. [27]  Based upon these results, we used 
low dose IL-2 (400 IU/ml) in our approach. The results demonstrate that T cells cultured 
in this dose of IL-2 proliferate well and showed low cytotoxicity against B16F0 tumor 
cells. (Table 3 and Figure 5)  
 
Meanwhile, many studies have reported that OK-432, a heat and penicillin-treated 
lyophilized preparation of the low-virulence strain of Streptococcus pyogenes, exhibits 
immunomodulatory activities and has potential antitumor therapeutic function, including 
the activation of DCs, neutrophils, macrophages, lymphocytes, and NK cells, and the 
induction of multiple cytokines production, such as IL-1, IL-2, IL-6, TNF-a, IFN-y, and 
IL-12. [40-46]  We hypothesized that OK-432, when combined with low dose IL-2, will 
enhance the proliferation and cytotoxicity of TILs in culture. As shown in Table 5 and 
Figure 6, TILs grew well in culture condition containing low dose IL-2 and OK-432 at a 
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concentration of 1 µg/ml. More importantly, cytotoxicity of T cells cultured in low dose 
IL-2 and OK-432 increased significantly (44%), when compared to that of T cells culture 
in low dose IL-2 alone (18%). 
 
DCs are antigen presenting cells and one of the best equipped APCs to prime the 
response of T cells because they can constitutively express MHC II antigens and 
numerous T cell co-stimulatory molecules. [30, 31] In order to further improve the tumor 
cell specific cytotoxicity of the cultured TILs, bone marrow derived DCs were first 
loaded with B16F0 tumor antigens and added into the in vitro culture system. When TILs 
are cultured in low dose IL-2 plus DCs, the cytotoxicity of the TILs improved 
significantly from 18% for low dose IL-2 alone to nearly 60% for low dose IL-2 plus 
DCs.  (Figure 7) The cytotoxicity of culture TILs increased to up to 73%, (Figure 8) 
when all the three reagents were added into the culture system, i.e., low dose IL-2 (400 
IU/ml), OK-432 (1 µg/ml), and DCs (TIL: DC=10:1). 
 
According to our results, proper concentration of TILs in culture is very important.  TILs 
cannot expand if the concentration is too low. On the other hand, nutritive elements 
become limiting if the concentration is too high. Another issue encountered in this 
research is that mice have to be euthanized when tumors are still small. The animal 
protocol requires that mice be euthanized when tumors start to become necrotic.  
Unfortunately, B16 melanoma tumors become necrotic when tumors are still small. This 
affects the collections of significant numbers of TILs from the tumors.  The number of 
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TILs in tumors is affected by tumor size.  The number of TILs may be small when the 
size of tumors is small.  This may also be a consequence of the immune system not being 
activated when tumors are small.  This directly means that only a small amount of TILs 
can be harvested, which negatively affects culture and phenotype analysis.   
 
In conclusion, an improved in vitro TIL culture system was established by adding OK-
432 into the culture system with low dose IL-2. Furthermore, when dendritic cells are 
added into the culture system, the cytotoxicity of the cultured TILs is significantly 
enhanced. 
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